title: Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis.
abstract: Reduced-intensity-conditioned allogeneic stem cell transplantation (SCT) remains a potentially curative approach for patients with relapsed/refractory Hodgkin lymphoma (HL) after an autologous stem cell transplantation. In the absence of an HLA-identical donor, haploidentical SCT (haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy) has been evaluated with favorable preliminary results. We evaluated 24 patients who underwent haplo-SCT for relapsed/refractory HL. The conditioning regimen consisted of cyclophosphamide, fludarabine, and total body irradiation. Graft-versus-host disease (GVHD) prophylaxis consisted of a calcineurin inhibitor, mycophenolate mofetil, and PT-Cy (50 mg/kg/day for 2 days) for all patients. After a median follow-up of 2 years, the cumulative incidence (CI) of nonrelapse mortality was 26% and the CI of grades II to IV acute GVHD and chronic GVHD were 17% and 24%, respectively. Estimation of progression-free and overall survival at 2 years were 54% and 66%%, respectively. Haplo-SCT is a valuable option for relapsed/refractory HL patients after a failed autologous SCT, with favorable survival and relatively low risk of GVHD.
authors.affiliation: Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: marceloplacerda@yahoo.com.br.
authors.forename: Marcelo Pitombeira de
authors.initials: MP
authors.lastname: Lacerda
authors.affiliation: Universidade Federal de São Paulo, São Paulo, Brazil; Hospital Sírio Libanês, São Paulo, Brazil.
authors.forename: Celso
authors.initials: C
authors.lastname: Arrais Rodrigues
authors.affiliation: Hospital Sírio Libanês, São Paulo, Brazil; Hospital e Maternidade São Camilo da Pompéia. São Paulo, Brazil.
authors.forename: André Domingues
authors.initials: AD
authors.lastname: Pereira
authors.affiliation: Hospital Sírio Libanês, São Paulo, Brazil.
authors.forename: Yana
authors.initials: Y
authors.lastname: Novis
authors.affiliation: Hospital e Maternidade São Camilo da Pompéia. São Paulo, Brazil; Instituto Brasileiro de Controle do Câncer (IBCC). São Paulo, Brazil.
authors.forename: Marina
authors.initials: M
authors.lastname: Fonseca
authors.affiliation: Hospital e Maternidade São Camilo da Pompéia. São Paulo, Brazil; Instituto Brasileiro de Controle do Câncer (IBCC). São Paulo, Brazil.
authors.forename: Roberto L
authors.initials: RL
authors.lastname: Silva
authors.affiliation: Hospital e Maternidade São Camilo da Pompéia. São Paulo, Brazil; Instituto Brasileiro de Controle do Câncer (IBCC). São Paulo, Brazil.
authors.forename: Maria C M A
authors.initials: MCMA
authors.lastname: Macedo
authors.affiliation: Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: Nelson
authors.initials: N
authors.lastname: Hamerschlak
authors.affiliation: Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: Iracema
authors.initials: I
authors.lastname: Esteves
authors.affiliation: A.C. Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Jayr
authors.initials: J
authors.lastname: Schmidt Filho
authors.affiliation: A.C. Camargo Cancer Center, São Paulo, Brazil.
authors.forename: Marina M
authors.initials: MM
authors.lastname: Nascimento
authors.affiliation: Hospital Sírio Libanês, São Paulo, Brazil.
authors.forename: Vanderson
authors.initials: V
authors.lastname: Rocha
mesh_terms: D000293:Adolescent; D000328:Adult; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D006680:HLA Antigens / Q000032:analysis / Q000235:genetics; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods / Q000401:mortality; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D000075442:Transplantation, Haploidentical / Q000379:methods* / Q000401:mortality; D055815:Young Adult
chemical_list: D006680:HLA Antigens
keywords: Haploidentical stem cell transplantation; Hodgkin lymphoma; Nonrelapse mortality; Post-transplantation cyclophosphamide; Reduced-intensity conditioning regimen